Dr. David Rabin is the chief innovation officer, co-founder, and co-inventor at Apollo Neuroscience, Inc. In his role, Dr. Rabin is developing Apollo Neuroscience’s IP portfolio and running clinical trials of the Apollo technology; the first scientifically-validated wearable system to improve focus, sleep, and access to meditative states by delivering gentle layered vibrations to the skin.  Dr. Rabin is a board-certified psychiatrist, translational neuroscientist, and inventor, and has been studying resilience and the impact of chronic stress in humans for more than 10 years. He has specifically focused his research on the clinical translation of non-invasive therapies that improve mood, focus, sleep, and quality of life in treatment-resistant illnesses. Dr. Rabin has six patent applications pending and many more on the way. Dr. Rabin received his MD in medicine and PhD in neuroscience from Albany Medical College and trained in psychiatry at Western Psychiatric Institute & Clinic at the University of Pittsburgh Medical Center. 

Dr. Rabin organized the world’s largest controlled study of psychedelic medicines in collaboration with colleagues at Yale, the University of Southern California, Modern Spirit, and MAPS (Multidisciplinary Association of Psychedelic Studies) to determine the mechanisms of the dramatic therapeutic benefits observed following psychedelic-assisted psychotherapy in treatment-resistant mental illness. Biological specimens are being collected from the first cohort of patients diagnosed with treatment-resistant PTSD in the MAPS FDA phase 3 double-blinded randomized placebo-controlled trial that began in 2019.

Dr. Rabin is also the Founder and Executive Director of the Board of Medicine, a nonprofit focused on democratizing health and treatment information by organizing and securing data to optimize public health. Dr. Rabin built and led a team of physicians and scientists to spearhead the development of the world’s first evidence-based peer-reviewed clinical guidelines for the safe use of medical cannabis and other complementary and alternative medicines. The Board of Medicine uses these guidelines to train and certify healthcare providers and industry partners, as well as to provide quality control standards for natural and prescription medicines to support the community goals of high-quality clinical research and harm-reduction.